Theorem Clinical Research

Drug Sponsors

Nicox acquires Eupharmed

Wednesday, November 27, 2013 11:48 AM

Nicox, an international pharmaceutical company focused on the ophthalmic market, has acquired Eupharmed, a privately-held Italian ophthalmic company, for $4.8 million in newly issued Nicox shares, plus milestones of up to $3.3 million. The acquisition provides Nicox with an established sales and marketing platform in Italy and a broad portfolio of eye care products. Eupharmed had sales of $4.9 million in 2012 and is expected to see full-year sales of approximately $5.3 million in 2013.

More... »

Flagship VentureLabs launches Seres Health

Friday, November 22, 2013 12:48 PM

Flagship VentureLabs has launched Seres Health after two years of development in stealth mode and $10.5 million in Series A financing during that period from Flagship Ventures and other investors. Seres Health is a clinical-stage therapeutics company developing novel products to treat a host of disease conditions based on novel scientific findings related to the human microbiome. Seres has developed a unique understanding of the functional nature of the human microbiome and has used this knowledge to pioneer Ecobiotic therapeutics, the first class of agents that addresses the ecological nature of the microbiome. 

More... »

Amicus Therapeutics acquires Callidus Biopharma, reduces workforce 14%

Friday, November 22, 2013 12:47 PM

Amicus Therapeutics, a biopharmaceutical company focused on therapies for rare and orphan diseases, has acquired Callidus Biopharma and announced restructuring of its biologics business strategy.

More... »

Cardiome acquires Correvio

Wednesday, November 20, 2013 12:52 PM

Cardiome Pharma has completed the acquisition of Correvio, a privately-held pharmaceutical company in Geneva, to accelerate Cardiome's launch of BRINAVESS (vernakalant IV) and reduce BRINAVESS build out costs.

More... »

Transcept Pharmaceuticals restructures board, cuts six jobs

Friday, November 15, 2013 01:27 PM

Transcept Pharmaceuticals, a specialty pharmaceutical company focused on development and commercialization of proprietary products that address important therapeutic needs in neuroscience, has announced plans to reduce expenses through a reduction in force and a restructuring of its board of directors. Transcept plans to adopt these changes to conserve cash while it evaluates strategies to maximize value for shareholders.

More... »

Dendreon restructures, cuts jobs to 820

Wednesday, November 13, 2013 12:22 PM

Biotech Dendreon has announced a company restructuring that includes cutting employment from 2,000 at its peak to approximately 820.

More... »

Liquidia Technologies launches Envisia Therapeutics

Wednesday, November 13, 2013 12:20 PM

Envisia Therapeutics, a new biotechnology company formed by privately-held Liquidia Technologies, has launched,  backed by $25 million in Series A financing. Envisia will focus on addressing unmet medical needs in various areas of ophthalmology. Envisia’s lead product, ENV515, is an extended-release formulation of a prostaglandin analogue providing glaucoma patients a sustained reduction in intraocular pressure (IOP) over many months after single administration.

More... »

Grifols to acquire Novartis blood transfusion diagnostics unit for $1.675 billion

Monday, November 11, 2013 04:42 PM

Novartis announced a definitive agreement to divest its blood transfusion diagnostics unit to Grifols for $1.675 billion. This transaction, requiring customary regulatory approvals, is expected to be completed in the first half of 2014.

More... »

Shire to acquire ViroPharma for $4.2 billion

Monday, November 11, 2013 02:55 PM

Shire and ViroPharma have entered a merger agreement in which Shire will acquire all the outstanding shares of ViroPharma in a cash deal valued at a total of $4.2 billion.

More... »

Salix Pharmaceuticals to acquire Santarus

Friday, November 8, 2013 12:11 PM

Salix Pharmaceuticals will acquire Santarus, a specialty biopharmaceutical company, in an all-cash transaction valued at approximately $2.6 billion. 

More... »

Subscribe to The CenterWatch Monthly



Browse by:


October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs